Cencora reported strong first quarter results, with revenue up 15% year-over-year to over $72 billion and adjusted earnings per share up 21%.
The company raised its fiscal 2024 full year guidance, reflecting the strength of its business and opportunities in the pharmaceutical market.
Cencora's core pharmaceutical distribution business showed outsized operating income growth, driven by strong volumes, favorable pricing trends, and effective expense management.
The International Healthcare Solutions segment performed well, with Global Specialty Logistics contributing to the strong performance. The company aims to become a leader in this space across major markets.
The company highlighted its focus on ESG goals and initiatives, including employee engagement, diversity and inclusion, and responsible operations.
While geopolitical risks were mentioned, Cencora emphasized its resilience as a healthcare distributor and its ability to navigate challenges in the supply chain.
Note: The transcript does not mention specific forecasts, outlooks, dividends, or buybacks.
Current Fair Value
Overvalued by 0.4% based on the discounted cash flow analysis.